How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,608 results for

Anti-Retroviral Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. The risk of hypertensive disorders of pregnancy among HIV-positive women receiving anti-retroviral therapy

The risk of hypertensive disorders of pregnancy among HIV-positive women receiving anti-retroviral therapy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation (...) by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about

2017 PROSPERO

102. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

therapy 3. Pharmaceutical equivalence and clinical interchangeability between lamivudine and emtricitabine 4. Use of efavirenz during pregnancy as part of first-line antiretroviral therapy: a public health perspective 5. Optimizing antiretroviral drugs for children: medium- and long-term priorities 6. Changing role of CD4 cell counts in HIV care and treatment 7. Scaling up viral load testing in resource-limited settings Supplementary sections to Chapter 9 – Guidance on operations and service delivery (...) of HIV/AIDS, WHO; Shirin Heidari, International AIDS Society; David Jamieson, PFSCM, United States of America; Janice Lee, Drugs for Neglected Diseases Initiative, Switzerland; Atieno Ojo, UNICEF.10 Community-based delivery of antiretroviral therapy We thank the meeting participants for their contribution: Marielle Bemelmans (Médecins Sans Frontières), Cephas Chikanda (Anova Health Institute), Tom Decroo (Institute for Tropical Medicine, Belgium), Bernard Michael Etukoit (The AIDS Support

2014 World Health Organisation HIV Guidelines

103. Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV

, Umscheid CA. Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV. Philadelphia: Center for Evidence-based Practice (CEP). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Retroviral Agents; HIV; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market (...) Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV Mitchell MD, O'Donnell JA, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, O'Donnell JA

2013 Health Technology Assessment (HTA) Database.

104. Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis

medicines 230 Importation of drug-resistant tuberculosis medicines 231 Storage and distribution in-country 231 Rational use 231 References 232 Appendices 233 CONTENTS viiAbbreviations 2LI second-line injectable drug AFB acid-fast bacillus Am amikacin Amx/Clv amoxicillin/clavulanate ART antiretroviral therapy ARV antiretroviral (drug) ATS American Thoracic Society AUC24 area under the concentration-time curve from 0 to 24 h BTS British Thoracic Society CD4 cells CD4+T lymphocytes Cf clofazimine Cfx cipro (...) . It was seen following the introduction of widespread anti- microbial use in the late 1940s and early 1950s, and served as a basis for the development of multidrug therapy for TB by Crofton and his colleagues in Edinburgh. When investigators introduced new drugs for treatment of TB as they were developed, they found that the bacterial populations selected by the treatment were resistant to the medications that had previously been used. Whereas the initial appearance of drug resistance is a ‘man-made’ phe

2013 International Union Against TB and Lung Disease

105. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

approaches to HIV prevention to achieve maximum impact on reducing HIV transmission and acquisition. ART (ANTIRETROVIRAL THERAPY) ARV (antiretroviral) drugs refer to the medicines themselves and not to their use. ART refers to the use of a combination of three or more Ar V drugs to achieve viral suppression. This generally refers to lifelong treatment. Synonyms are combination Ar T and highly active Ar T. ART for prevention is used to describe the HIV prevention benefits of A r T. Eligible for ART refers (...) Library Cataloguing-in-Publication Data Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: r ecommendations for a public health approach June 2013. 1.HIV infections – drug therapy. 2.HIV infections – prevention and control. 3.Anti-r etroviral agents – therapeutic use. 4.Guideline. I.World Health Organization. ISBN 978 92 4 150572 7 (NLM classification: WC 503.2) © World Health Organization 2013 All rights reserved. Publications of the World Health

2013 World Health Organisation HIV Guidelines

106. Epidemiology of High-risk Human Papillomavirus and Cervical Lesions in African women living with HIV/AIDS: Effect of Anti-Retroviral Therapy. Full Text available with Trip Pro

Epidemiology of High-risk Human Papillomavirus and Cervical Lesions in African women living with HIV/AIDS: Effect of Anti-Retroviral Therapy. To describe the effect of antiretroviral therapy (ART) and HIV-related factors on high-risk human papillomavirus (HR-HPV) and high-grade cervical intraepithelial neoplasia lesions (CIN2+) among women living with HIV/AIDS (WLHA) in sub-Saharan Africa.Prospective cohort of WLHA in Ouagadougou, Burkina Faso (BF) and Johannesburg, South Africa (SA

2016 AIDS

107. The Effect of HIV and the Modifying Effect of Anti-Retroviral Therapy (ART) on Body Mass Index (BMI) and Blood Pressure Levels in Rural South Africa Full Text available with Trip Pro

The Effect of HIV and the Modifying Effect of Anti-Retroviral Therapy (ART) on Body Mass Index (BMI) and Blood Pressure Levels in Rural South Africa High BMI and blood pressure are leading chronic disease risk factors in South Africa. Longterm effects of HIV and ART on adiposity and blood pressure are poorly understood, and direct comparisons of risk factor trajectories in HIV- versus HIV+ populations are rare.In 2003 and 2010, height, weight, and blood pressure were recorded in a study

2016 PloS one

108. Hepatitis B co-infection in HIV-infected patients receiving antiretroviral therapy at the TC Newman Anti Retroviral Treatment Clinic in Paarl, Western Cape Full Text available with Trip Pro

Hepatitis B co-infection in HIV-infected patients receiving antiretroviral therapy at the TC Newman Anti Retroviral Treatment Clinic in Paarl, Western Cape Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection in South Africa is estimated to be between 5% and 23%; however, only limited evidence is available. Co-infection increases the risk of chronification of HBV, liver cirrhosis and death.To assess the HBV and/or HIV co-infection rate amongst the adult antiretroviral

2016 Southern African journal of HIV medicine

109. HIV sero-discordance among married HIV patients initiating anti-retroviral therapy in northern Vietnam Full Text available with Trip Pro

HIV sero-discordance among married HIV patients initiating anti-retroviral therapy in northern Vietnam In many countries in Asia, the HIV epidemic is in a concentrated phase, with high prevalence in certain risk groups, such as men who inject drugs. There is also a rapid increase of HIV among women. The latter might be due to high levels of sero-discordant couples and increasing transmission from male to female partners over time.All adult married patients initiating antiretroviral treatment (...) was significantly higher among married males, 71% had spouses not infected, than married females, of whom 18% had spouses not infected. Other factors associated with a high rate of sero-discordance were injection drug use (IDU) history, tuberculosis (TB) history and the availability of voluntary counselling and testing (VCT) in residential locations. High sero-concordance was associated with college/university education.The sero-discordance was significantly higher among married males than married females

2016 AIDS research and therapy

110. Adherence to anti-retroviral drugs Full Text available with Trip Pro

Adherence to anti-retroviral drugs 27121524 2017 05 19 2018 11 13 0971-5916 143 2 2016 Feb The Indian journal of medical research Indian J. Med. Res. Adherence to anti-retroviral drugs. 245 10.4103/0971-5916.180227 Roy Manas Pratim MP Department of Pediatrics, Safdarjung Hospital, New Delhi 110 029, India. eng Letter India Indian J Med Res 0374701 0971-5916 0 Anti-Retroviral Agents IM Adult Anti-Retroviral Agents adverse effects Antiretroviral Therapy, Highly Active adverse effects Female HIV (...) Infections complications drug therapy Humans Male Medication Adherence 2016 4 29 6 0 2016 4 29 6 0 2017 5 20 6 0 ppublish 27121524 IndianJMedRes_2016_143_2_245_180227 10.4103/0971-5916.180227 PMC4859135 Indian J Med Res. 2015 Sep;142(3):301-10 26458346 Indian J Med Res. 2011 Dec;134(6):835-49 22310817 Indian J Community Med. 2013 Apr;38(2):74-82 23878418 Indian J Med Res. 2008 Jan;127(1):28-36 18316850 AIDS Res Ther. 2009 Apr 28;6:7 19400929

2016 The Indian journal of medical research

111. Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study Full Text available with Trip Pro

Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study Regimen change is a major challenge for the sustainability of human immunodeficiency virus (HIV) treatment program. In a resource limited setting where treatment options are limited, designing strategies to increase the durability of original regimen are essential. However, information's (...) on rate of initial regimen change and its predictors is scarce in Ethiopia. Therefore, the purpose of this study was to assess the rate of initial highly active anti retroviral therapy (HAART) regimen change and its predictors among adult HIV patients at the University of Gondar Referral Hospital, Northwest Ethiopia.An institutional based retrospective follow up study was conducted among 410 adult HIV patients started HAART from January 2010 to December 2014. Simple random sampling technique was used

2016 AIDS research and therapy

112. Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients Full Text available with Trip Pro

Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients Data on the prevalence of dyslipidaemia and associated risk factors in HIV-infected patients from sub-Saharan Africa is sparse. We performed a cross-sectional analysis in a cohort of HIV-infected South African adults.We studied HIV-infected patients who were either antiretroviral therapy (ART)-naive or receiving non-nucleoside reverse transcriptase inhibitor (NNRTI)-based or protease

2016 PloS one

113. Impact of HIV Infection and Anti-Retroviral Therapy on the Immune Profile of and Microbial Translocation in HIV-Infected Children in Vietnam Full Text available with Trip Pro

Impact of HIV Infection and Anti-Retroviral Therapy on the Immune Profile of and Microbial Translocation in HIV-Infected Children in Vietnam CD4⁺ T-lymphocyte destruction, microbial translocation, and systemic immune activation are the main mechanisms of the pathogenesis of human immunodeficiency virus type 1 (HIV) infection. To investigate the impact of HIV infection and antiretroviral therapy (ART) on the immune profile of and microbial translocation in HIV-infected children, 60 HIV

2016 International journal of molecular sciences

116. Dyslipidemia, Diet, and Physical Exercise in Children on Treatment with Anti-Retroviral Medication in El Salvador: A Cross-Sectional Study. Full Text available with Trip Pro

Dyslipidemia, Diet, and Physical Exercise in Children on Treatment with Anti-Retroviral Medication in El Salvador: A Cross-Sectional Study. Dyslipidemias are common in HIV-infected children, especially if treated with protease inhibitors, but there are few data on how to treat dyslipidemias in this population. We estimated the dyslipidemia prevalence and its association with treatment, diet and physical exercise in children on antiretroviral treatment at the El Salvador reference center (...) for pediatric HIV care (CENID).Information was gathered regarding socio-demographic characteristics, treatment, diet and physical activity of 173 children aged 5-18 years and receiving antiretroviral therapy. Triglycerides, total cholesterol, low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), viral load and CD4 T-lymphocytes were measured. Abnormal concentrations were defined as triglycerides ≥130 mg/dL in 10- to 18-year olds and ≥100 mg/dL in <10-year olds; total cholesterol ≥200 mg/dL; LDL

2016 Pediatric Infectious Dsease Journal

117. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

as it does the impact of changing the recommended first-line anti-retroviral therapy from an Efavirenz-based regimen to dolutegravir – now increasingly seen as the standard recommended first-line treatment, even in sub-Saharan Africa. The predicted medical gains include 13,000 HIV transmissions averted over 5 years. This will not solve the problem of HIV/AIDS in India, but will give the rate of new infections a further nudge in the downward direction. In addition, it will improve five-year survival from (...) 76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost

2018 Sexually Transmitted Infections blog

118. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

as it does the impact of changing the recommended first-line anti-retroviral therapy from an Efavirenz-based regimen to dolutegravir – now increasingly seen as the standard recommended first-line treatment, even in sub-Saharan Africa. The predicted medical gains include 13,000 HIV transmissions averted over 5 years. This will not solve the problem of HIV/AIDS in India, but will give the rate of new infections a further nudge in the downward direction. In addition, it will improve five-year survival from (...) 76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost

2018 Sexually Transmitted Infections blog

119. Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes Full Text available with Trip Pro

Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes The exacerbation of HIV-1 associated dyslipidemia seen in a subset of patients receiving anti-retroviral therapy suggests that genetic factors put these individuals at greater risk of cardiovascular disease. Single nucleotide polymorphisms (SNPs) within genes of and influencing the reverse cholesterol transport (RCT) pathway (...) are associated with lipid levels but little is known regarding their copy number variation (CNV). This form of quantitative genetic variation has the potential to alter the amount of gene product made, thereby also influencing lipid metabolism.To examine if CNV in RCT pathway genes was associated with altered serum lipid profiles in HIV-positive individuals receiving therapy, we designed a custom multiplex ligation-dependent probe amplification assay to screen 16 RCT genes within a subset of individuals from

2015 BMC research notes

120. Outcomes of Children on Anti-Retroviral Therapy in Nurse-Led Clinics in Rural Lesotho. (Abstract)

Outcomes of Children on Anti-Retroviral Therapy in Nurse-Led Clinics in Rural Lesotho. This survey assessed virologic outcomes of children on antiretroviral therapy and potential predictors in 10 nurse-led clinics in Lesotho. Viral suppression was achieved in 72% of the 191 children. No predictors for virologic outcome were found, underlining the need for routine viral load testing in resource-limited settings to achieve 90-90-90.

2015 Pediatric Infectious Dsease Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>